AU1786999A - Diagnosis of sepsis using the lps-binding moiety of alkaline phosphatase - Google Patents
Diagnosis of sepsis using the lps-binding moiety of alkaline phosphatase Download PDFInfo
- Publication number
- AU1786999A AU1786999A AU17869/99A AU1786999A AU1786999A AU 1786999 A AU1786999 A AU 1786999A AU 17869/99 A AU17869/99 A AU 17869/99A AU 1786999 A AU1786999 A AU 1786999A AU 1786999 A AU1786999 A AU 1786999A
- Authority
- AU
- Australia
- Prior art keywords
- alkaline phosphatase
- lps
- sample
- binding site
- lps binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108020004774 Alkaline Phosphatase Proteins 0.000 title claims description 145
- 102000002260 Alkaline Phosphatase Human genes 0.000 title claims description 145
- 230000027455 binding Effects 0.000 title claims description 92
- 206010040047 Sepsis Diseases 0.000 title claims description 21
- 238000003745 diagnosis Methods 0.000 title claims description 10
- 238000000034 method Methods 0.000 claims description 65
- 230000000694 effects Effects 0.000 claims description 40
- 239000003446 ligand Substances 0.000 claims description 37
- 210000002966 serum Anatomy 0.000 claims description 29
- 210000001519 tissue Anatomy 0.000 claims description 29
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 claims description 20
- 239000012530 fluid Substances 0.000 claims description 19
- 238000003556 assay Methods 0.000 claims description 18
- 230000007423 decrease Effects 0.000 claims description 17
- 208000037487 Endotoxemia Diseases 0.000 claims description 13
- 210000004369 blood Anatomy 0.000 claims description 13
- 239000008280 blood Substances 0.000 claims description 13
- 208000027096 gram-negative bacterial infections Diseases 0.000 claims description 13
- 208000014674 injury Diseases 0.000 claims description 11
- 230000008733 trauma Effects 0.000 claims description 11
- 201000010099 disease Diseases 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 208000015181 infectious disease Diseases 0.000 claims description 8
- 239000003550 marker Substances 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 8
- 239000000872 buffer Substances 0.000 claims description 7
- 206010008635 Cholestasis Diseases 0.000 claims description 6
- 231100000359 cholestasis Toxicity 0.000 claims description 6
- 230000007870 cholestasis Effects 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 6
- 238000002560 therapeutic procedure Methods 0.000 claims description 6
- 230000000052 comparative effect Effects 0.000 claims description 4
- 210000000936 intestine Anatomy 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 238000000746 purification Methods 0.000 claims description 4
- 108060003951 Immunoglobulin Proteins 0.000 claims description 3
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 3
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 3
- 210000000988 bone and bone Anatomy 0.000 claims description 3
- 102000018358 immunoglobulin Human genes 0.000 claims description 3
- 230000000302 ischemic effect Effects 0.000 claims description 3
- 210000004185 liver Anatomy 0.000 claims description 3
- 238000002306 biochemical method Methods 0.000 claims description 2
- 210000001124 body fluid Anatomy 0.000 claims description 2
- 239000010839 body fluid Substances 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims description 2
- 238000012544 monitoring process Methods 0.000 claims description 2
- 238000011084 recovery Methods 0.000 claims description 2
- 238000000926 separation method Methods 0.000 claims description 2
- 238000001356 surgical procedure Methods 0.000 claims description 2
- 241000192125 Firmicutes Species 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000002158 endotoxin Substances 0.000 description 91
- 229920006008 lipopolysaccharide Polymers 0.000 description 89
- 102000004190 Enzymes Human genes 0.000 description 13
- 108090000790 Enzymes Proteins 0.000 description 13
- 239000000047 product Substances 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 5
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 4
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 4
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- 210000002826 placenta Anatomy 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 208000035143 Bacterial infection Diseases 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 208000019423 liver disease Diseases 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- BLFWHYXWBKKRHI-JYBILGDPSA-N plap Chemical compound N([C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(=O)[C@@H]1CCCN1C(=O)[C@H](CO)NC(=O)[C@@H](N)CCC(O)=O BLFWHYXWBKKRHI-JYBILGDPSA-N 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 208000003322 Coinfection Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 239000013060 biological fluid Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000030609 dephosphorylation Effects 0.000 description 2
- 238000006209 dephosphorylation reaction Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 229930004094 glycosylphosphatidylinositol Natural products 0.000 description 2
- 208000027136 gram-positive bacterial infections Diseases 0.000 description 2
- 231100000234 hepatic damage Toxicity 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 230000003870 intestinal permeability Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 230000008818 liver damage Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 2
- 230000011164 ossification Effects 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000008940 Alkaline Phosphatase assay kit Methods 0.000 description 1
- 206010003011 Appendicitis Diseases 0.000 description 1
- 208000031504 Asymptomatic Infections Diseases 0.000 description 1
- 208000031729 Bacteremia Diseases 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 206010018001 Gastrointestinal perforation Diseases 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 201000005624 HELLP Syndrome Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000052508 Lipopolysaccharide-binding protein Human genes 0.000 description 1
- 108010053632 Lipopolysaccharide-binding protein Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101000574441 Mus musculus Alkaline phosphatase, germ cell type Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 241001222774 Salmonella enterica subsp. enterica serovar Minnesota Species 0.000 description 1
- 206010053879 Sepsis syndrome Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 201000005008 bacterial sepsis Diseases 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000001865 kupffer cell Anatomy 0.000 description 1
- RLJMLMKIBZAXJO-UHFFFAOYSA-N lead nitrate Chemical compound [O-][N+](=O)O[Pb]O[N+]([O-])=O RLJMLMKIBZAXJO-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 230000003448 neutrophilic effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 201000011461 pre-eclampsia Diseases 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 102000014452 scavenger receptors Human genes 0.000 description 1
- 108010078070 scavenger receptors Proteins 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000008718 systemic inflammatory response Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 231100000925 very toxic Toxicity 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
- G01N33/567—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds utilising isolate of tissue or organ as binding agent
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
WO 00/37943 PCT/NL98/00722 1 DIAGNOSIS OF SEPSIS USING THE LPS-BINDING MOIETY OF ALKALINE PHOSPHATASE 5 PRESENT STATE OF THE ART Alkaline phosphatase (AP) is an ecto-enzyme bound via a glycosyl-phosphatidyl-inositol (GPI)-anchor to the plasma membrane of many cell types including endothelial and epithelial cells, osteoblasts, fibroblasts, and hepatocytes. The enzyme is also present in specific granula of neutrophils. Consequently, all organs 10 contain abundant alkaline phosphatase activity. In addition, enzyme activity is also present in plasma. Increased levels of AP activity in blood are found when bone formation is evident for instance during embryogenesis and childhood (3). Also hepatic diseases like cholestasis are characterized by high serum AP levels and an enhanced expression of AP 15 activity upon plasma membranes of hepatocytes. This enzyme is therefore a generally accepted serum marker for the diagnosis of this disease (4). Release from neutrophilic granula after activation of this cell type may also contribute to the enhanced serum AP activity found during inflammatory processes. The physiological significance of this enzyme induction in liver diseases and inflammatory processes is unknown. A role of AP 20 during the process of bone formation has been documented in vitro and in vivo. Recent studies have demonstrated that AP is able to dephosphorylate endotoxin or lipopolysaccharide (LPS). LPS is a constituent of the cell wall of Gram-negative bacteria and it is very toxic to man and most animal species. It induces fulminant inflammatory reactions which may be life threatening when these responses 25 occur within the bloodstream. This disease is referred to as 'sepsis' or 'systemic inflammatory response syndrome (SIRS)' and is lethal in approximately 35% of all cases. LPS may enter the bloodstream after bacterial infections, during hepatic diseases or when intestinal permeability is enhanced for instance during or after ischemic occurrences. High concentrations of LPS are present in the gastro-intestinal tract due to 30 production by E. coli bacteria, Enterobacteriaceae, and many other bacterial species. Since virtually no LPS is found in plasma, the gastrointestinal tract obviously has an effective barrier. This barrier is characterized by a high AP expression similar to the blood brain barrier where neuro endothelial cells also express a high AP activity.
WO 00/37943 PCT/NL98/00722 2 An enhanced intestinal permeability for LPS has been documented in patients with gastro-intestinal perforations, appendicitis or peritonitis but also in patients with alcoholic abuse, after traumatic events such as burns, major surgical operations to the gastro-intestinal tract and after sepsis. Most of these latter cases are characterized by 5 post-ischemic reperfusion injury to the intestinal wall and concomitant release of an array of inflammatory mediators which affect the vascular permeability in the intestine thus causing leakage of LPS from the intestinal lumen into the vena porta. In normal conditions the liver plays an important role in the removal of LPS from the circulation, in particular the Kupffer cell is important in this respect. However, in many hepatic 10 diseases this function is impaired which in turn may lead to endotoxemia. Phosphate groups within the lipid A moiety of LPS determine several biological responses to this bacterial product. The lipid A moiety is the relatively constant part of this otherwise highly variable molecule. Generally, two phosphate groups are present upon this lipid A moiety in addition to a variety of phosphate groups 15 within the polysaccharide tail. Whereas phosphate groups within the polysaccharide tail do not influence the inflammatory response upon LPS, the phosphate groups within the lipid A moiety are of major importance. It has been demonstrated that mono-phosphoryl lipid A is a weak inducer of macrophage responses and is non-toxic to chickens and rabbits, whereas native, di-phosphoryl lipid A is a potent activator of macrophages and 20 lethal to most mammals. The dephosphorylation of LPS by alkaline phosphatase may therefore be important in vivo and this creates new insights into the physiological role of this enzyme. This new insight may have many therapeutic implications. Document PCT/NL94/00189 describes the therapeutic application of alkaline phosphatase to treat all 25 kinds of the clinical complications induced by LPS. DESCRIPTION OF THE INVENTION In summary, the examples show that serum AP activity declines in patients 30 with established Gram-negative sepsis, whereas serum AP activity is unaffected or even is slightly enhanced in patients with established Gram-positive sepsis. This new finding may be explained by the binding of LPS to AP enzymes as demonstrated herein. This binding either may cause a change in the distribution of AP, thus reducing half-life in WO 00/37943 PCT/NL98/00722 3 serum or it may affect the enzyme activity directly. Based on all these observations, and considering the new insight on the role of AP in vivo as an LPS detoxifying enzyme (described in document PCT/NL94/00189 ), it can be concluded that AP has a binding site for LPS and that the binding of this ligand to the enzyme has important implications. 5 Early detection of endotoxemia in patients with liver failure, severe burns or other trauma's (e.g. after organ transplantations) is important but rather complicated. Reliable and sensitive methods which measure free LPS in serum and which take the endotoxin detoxifying capacity of serum also into account are not available yet. In addition, methods determining the amount of LPS in serum do not give any information 10 about the preceding situation. This is particularly relevant in view of the short half-life of LPS in the bloodstream. Detection methods to measure the binding of LPS to AP as such are feasible and these methods can be applied for diagnostic purposes to discriminate between Gram-positive and Gram-negative sepsis or to assess the severity of the disease. The degree of occupation of the binding site appears to be an early marker 15 for this disease. Thus a valuable new diagnostic tool is described here. In addition, based upon the insight that AP has a specific binding domain for LPS, new LPS binding systems can be developed that bind to this domain. These domains are able to remove LPS from fluid or tissue. ligands interacting with AP may also be used for the purification of AP from crude or partially purified biological sources (e.g. milk, culture 20 media, tissue samples) Also systems applying the LPS binding domain of AP can also be used for therapeutic purposes. Thus the invention describes the use of ligands to the LPS-binding site of alkaline phosphatase. Examples of such ligands are mono- or polyclonal antibodies against this ligand either in their natural occurring form or as Fab-fragments, single 25 chains, or otherwise modified immunoglobulins. In addition, labeled LPS, lipid A, derivatives of both substances or products mimicking the tertiary structure of lipid A can be used as ligands for the LPS binding site in AP enzymes. It is possible to design such on the basis of computer modelling. The product can be produced synthetically using chemical means. There are references detailing production of lipid A like structures 30 using chemical means (1,2). Use of recombinant DNA technology to engineer the required structure is also possible as is chemical modification of lipid A like structures. Measurement of the concentration of free LPS-binding domains on alkaline phosphatase for diagnostic purposes can be done using these products. Subsequently, this WO 00/37943 PCT/NL98/00722 4 concentration can be related to the total concentration of AP enzymes, or to the total enzyme activity in biological fluids which will yield additional information about the presence of LPS and the LPS-detoxifying capacity in biological fluids. Thus the method acording to the invention consists of diagnosis of onset of 5 endotoxemia or sepsis due to Gram negative bacterial infection said method comprising monitoring of the degree of AP occupancy of LPS binding sites on alkaline phosphatase in a sample of tissue or fluid derived from a patient, wherein the degree of AP occupancy is associated with presence or absence of Gram negative bacterial infection. Specifically such a method wherein the . degree of AP occupancy of LPS binding sites 10 on alkaline phosphatase in the sample is lower than that of an equivalent sample type of an individual free of Gram negative infection. By way of example the degree of AP occupancy of LPS binding sites on alkaline phosphatase in a sample or tissue or fluid derived from a patient, is monitored over a period of time, wherein a decline of the degree of AP occupancy indicates Gram negative bacterial infection. In such a case the 15 degree of AP occupancy of LPS binding sites on alkaline phosphatase in the sample is determined and when onset of decline in the degree of AP occupancy is ascertained this indicates onset of Gram negative bacterial infection. It is also possible depending on the values determined that the degree of AP occupancy of LPS binding sites on alkaline phosphatase may also indicate a mixed infection of Gram negative and Gram positive 20 bacteria. The test may indicate the onset of sepsis but may also identify those individuals at risk for sepsis e.g. those individuals at risk for sepsis e.g. persons with structural low AP levels in tissue or blood, due to a genetic defect or due to a chronic illness such as Rheumatoid arthritis, brain oedema, Alheimer, ischemic heart diseases or inflammatory bowel diseases. In addition the test may be used to assess (subclinical) infections in 25 pregnant women. These subclinical infections may provoke the HELLP syndrome or pre eclampsia in the mother or affect the condition of the child by causing intraurine growth retardation of the foetus or even inducing pre-term delivery. As a consequence the test described here can be used to prevent pathology to the new born child. In a method according to the invention the sample to be determined can be subjected to binding with 30 a ligand for the LPS binding site on alkaline phosphatase followed by determination of the degree of binding of the ligand. Any ligand with the required specificity can be used. The selection will depend on the type of sample to be tested and the degree of sensitivity to be reached. Quite specifically suitable ligands can be selected LPS, Lipid A, an LPS WO 00/37943 PCT/NL98/00722 5 binding site antibody against alkaline phosphatase, a Fab fragment with LPS binding site binding ability on alkaline phosphatase, a single chain fragment of an immunoglobulin having LPS binding site binding activity on alkaline phosphatase. Alternatively other ligands e.g. developed on the basis of computer modelling of the binding system of LPS 5 and lipid A with alkaline phosphatase can also be used. The ligands may be naturally occurring molecules or synthetic molecules. The synthetic molecules may be produced using chemical or biochemical i.e. recombinant DNA technology methods. Preferably a method according to the invention employs an LPS binding site binding ligand with at least the affinity for the LPS binding site of alkaline phosphatase of LPS. Also a method 10 according to the invention may suitably employ an LPS binding site binding ligand with at least the affinity for the LPS binding site of alkaline phosphatase of lipid A. The required degree of specificity and affinity can be ascertained using standard tests for comparing specificity and affinity of a compound for a substrate. In a method according to the invention the degree of AP occupancy of LPS binding sites on alkaline 15 phosphatase can be determined by assessment of the dephosphorylating capacity of alkaline phosphatase in the sample. In such a method the ratio of dephosphorylating alkaline phosphatase to non dephosphorylating alkaline phosphatase is determined. The ratio can be determined using the values obtained by assessment of total alkaline phosphatase activity using biochemical methods to determine dephosphorylating activity 20 and by assessment of total amounts of alkaline phosphatase using antibodies and calculating the ratio of these values. There are numerous routes available to the skilled person to carry out such assessments. We refer by way of example to references 5 and 6. The content hereof is incorporated by reference. It will immediately be apparent what other alternative known methods can be applied to arrive at the required data. 25 The sample to be used in the method according to the invention can be a sample derived from a patient. Such a sample can be from blood or tissue. The sample must be a sample treated such that any alkaline phosphatase present is not removed prior to the assay. Such a sample can be selected from the group consisting of blood and tissue. The blood sample can for example be serum. The tissue sample is preferably 30 other than bone as alkaline phosphatase levels are generally high in bone. The tissue that is suitable for example can be selected from liver and intestines. A biopt can be taken in a manner known per se. Blood and serum samples may also be prepared in the usual manner.
WO 00/37943 PCTINL98/00722 6 The method according to the invention can be carried out with a sample from a cholestasis free patient. The method according to the invention can also be carried out on a patient with cholestasis. The values determined for the degree of LPS binding can be compared to standard values of healthy and/or sick patients to ascertain 5 the correct diagnosis. Alternatively the method according to the invention can comprise carrying out the assay described above in any of the described embodiments and in addition also comprising a further assay of a sample from the patient for another disease related to increase of alkaline phophatase activity such as cholestasis. The further assay must preferably then employ a method avoiding determination of alkaline phosphatase 10 level. Numerous articles describing such alternative assays for alkaline phosphatasae associated diseases are available in articles covering said diseases and the content thereof is incorporated by reference. A suitable embodiment of the method according to the invention wherein the further assay is carried out is when the alkaline phosphatase assay according to the invention reveals no decline in AP occupancy of LPS binding sites of 15 alkaline phosphatase. Suitably the method according to any of the embodiments of the invention comprises a method wherein the sample is taken from an individual at risk of Gram negative bacterial infection. The sample can for example be taken from an individual either both prior to and following trauma. It can also be taken shortly after having undergone trauma. Quite interesting cases of trauma concern surgery, burns and 20 ischemic trauma. As hospitals form notorious sources of infection suitably the method according to the invention can comprise assessment of a sample taken from an individual during hospitalisation. In a method according to the invention the sample can be taken a number of times over a period of time. The data can be compared with eachother thus revealing the 25 level of AP occupancy over time. The values can however also be compared with a standard value for a healthy or sick individual. The values can also be correlated to various characteristics of the patient e.g. gender, age, body weight, tissue or fluid type to be tested. The method thus reveals whether the degree of AP occupancy is indicative of endotoxemia or sepsis. A method according to the invention can comprise taking samples 30 over a period of time as long as the individual is at risk of infection i.e. during hospitalisation or post trauma recovery. The invention also envisages kits for carrying out the diagnostic method according to the invention. Such a kit can comprise alkaline phosphatase LPS binding WO 00/37943 PCT/NL98/00722 7 site binding ligand and instructions for carrying out an assay according to any of the abovementioned embodiments. The kit can further comprise any additional components required for such assay e.g. detectable marker, buffer, containers. Also suitable as additions to the kit are comparative samples or data charts e.g. standard curves or data 5 concerning relevant data of alkaline phosphatase values. A kit comprising alkaline phosphatase LPS binding site binding ligand for carrying out an assay according to any of the abovementioned embodiments and any additional component required for such assay being selected from the following group consisting of detectable marker, buffer, containers, comparative samples, data charts e.g. standard curves or data concerning 10 relevant data of alkaline phosphatase values is also part of the invention. The ligands envisaged have been described in the embodiments of the method as disclosed above and in the claims and examples. In addition the invention covers a method for removing LPS from tissue or fluid said method comprising contacting the LPS binding site of alkaline phosphatase 15 with the tissue or fluid to be treated followed by separation of the LPS binding site and the tissue or fluid after the the LPS binding site has bound the LPS present in the fluid or tissue, with the proviso the ligand is neither alkaline phosphatase nor a derivative of alkaline phosphatase having dephosphorylating activity. Thus the LPS can be removed from the tissue or fluid. Clearly the binding must occur under circumstances that do not 20 damage the fluid or tissue to be purified. Such conditions will be readily apparent to the skilled person used to dealing with such tissue or fluid. By way of example the LPS-binding domain of AP itself can be coupled to a non-soluble carrier to remove LPS from tissue or fluids. Suitable fluids to be treated are cell-culture media, liquids used for organ perfusion or preservation, blood, milk or any other therapeutic product 25 administered to a person. Ligands which bind to the LPS binding site of AP may also be used for purification of AP itself from tissue or body fluids or other biological production systems. The invention also covers a method for therapy of endotoxemia or sepsis said method comprising administration of a pharmaceutically effective amount of the 30 LPS binding site of alkaline phosphatase in a systemically acceptable form with the proviso the ligand is neither alkaline phosphatase nor a derivative of alkaline phosphatase having dephosphorylating activity. Any conventional medicinal dosage form will suffice. The dosage regime to be followed will depend on the condition of the patient, gender, WO 00/37943 PCT/NL98/00722 8 age, body weight by way of example and the physician will be able to determine the best regime to apply. The LPS-binding domain as such or in the form of a derivative of alkaline phosphatase, said derivative not having dephosphorylating activity may be applied therapeutically to treat a patient with a systemic inflammatory response 5 syndrome or to prevent endotoxemia in patients at risk for such a complication. Binding of LPS in blood to this particular domain may prevent the interaction of LPS with other endogenous receptors in serum and upon plasma membranes of endothelial cells or macrophages such as LPS-binding protein, CD-14 and scavenger receptors. As a consequence, the inflammatory response upon LPS will be attenuated. 10 The invention also covers other therapy and diagnostic applications of the ligands described in the description of the invention and a method of purification of AP itself using LPS or any AP binding derivative thereof i.e. the other ligands mentioned. EXPERIMENTAL DATA EXPERIMENT I 15 These reports prompted us to examine the serum levels of AP during endotoxemia. It is generally accepted that AP is a marker of liver damage, and LPS is known to induce directly or indirectly damage to this organ. An increase in serum AP activity in patients with sepsis has been frequently documented and was also expected in mice with endotoxemia. However, after intravenous administration of LPS from E.coli 20 (strain 055:B5, Sigma Chemical Co, USA, 2.5 mg/kg b.w.) to Balb/c mice (male, 20-25 g) at t=0 a rapid and sharp decline in serum AP activity was observed as compared to mice receiving saline (fig. 1). A similar decline was found after intraperitoneal administration of E.coli bacteria (ATCC 25922, 2 x 109 CFU) to mice (fig. 1). Evaluation of clinical data of patients with recurrent endotoxemia revealed 25 also a rapid primary sharp decline in serum AP activity, followed by a strong increase in the following days. It is believed that the first sharp decline of AP is caused by LPS. This decline enables residual LPS to evoke its inflammatory action thereby activating the destructive responses seen in sepsis patients. Clinically this primary reaction of AP decline has hitherto not been observed. Therefore to enable a fast detection of sepsis fast 30 detection of declining AP levels is of most importance. The method described in the present document enables the measurement of such a fast kinetic change in AP levels. The basis in this lies in the fact that free and thereby fully active AP in plasma declines rapidly upon binding to LPS. The secondary increase in serum AP levels seen in most WO 00/37943 PCT/NL98/00722 9 patients may either reflect liver damage or may be induced by interleukin 6 or other inflammatory mediators which attenuate the expression of AP activity as recent studies have pointed out. 5 EXPERIMENT II We examined subsequently 64 patients in the intensive care unit suffering from sepsis. The pathogenic bacteria causing the sepsis syndrome were identified in all of these cases. Patients with endotoxemia (n=16) were compared with patients with Gram-positive bacterial infections (n=30), which lack LPS in serum. The patients had a 10 variety of underlying diseases, but patients with cholestasis, which is associated with an increased AP excretion, were excluded. Blood samples were routinely assayed for AP during hospitalization. Changes in serum AP levels were related to day O, that is, the day of admission to the intensive care unit of the hospital. We calculated the change in serum AP activity, relative to day 0, before and after the blood samples became positive 15 for bacteria or bacterial products (LPS). These studies demonstrate that a decline in serum AP activity is an early marker of sepsis: the decrease preceded the bacteremia (fig. 2). Moreover, the data show that Gram-negative bacterial infections can be discriminated from Gram-positive bacterial infections because patients with established Gram-negative infections displayed a decline in serum AP activity (mean slope= -21.5) 20 whereas patients with a proven Gram-positive bacterial sepsis showed a slight increase (mean slope= 10.9) relative to day zero. Note that at day zero (admittance to Intensive Care) the actual value of serum AP may have been affected already. Patients with a mixed infection (both Gram-positive and Gram-negative, n= 18) showed an intermediate change in the serum AP levels (mean slope= 0.6). The rapid diagnosis of Gram-positive 25 versus a Gram-negative bacterial infection is particularly important in acute situations where an immediate start an effective antibacterial therapy is essential. To date, this diagnosis can only be made after a successful culture of the pathogenic bacteria, which takes usually two days. 30 EXPERIMENT III We hypothesized that the decline in serum AP levels was caused by an increased turn-over of the enzyme. We therefore examined whether a direct binding between LPS and AP enzymes occurred and whether this binding would influence the WO 00/37943 PCT/NL98/00722 10 enzyme activity. Placental AP (6.7 U/ml), isolated from fresh human placenta's was incubated with LPS from E.coli (strain 055:B5, Sigma Chemical co; 1 mg /ml) for 10 minutes at room temperature. Subsequently, AP was subjected to FPLC analysis. The FPLC was equipped with an anion-exchange column (mono-Q HR 5/5, Pharmacia, 5 Sweden) and UV detection (280 nm). PlAP was injected in 0.2 M Tris/HCl buffer (pH 7.4) containing MgC12 with or without LPS. Elution was performed in Tris/HC1 buffer (pH 7.4) with a flow rate of 0.5 ml/min and a NaCl gradient ranging from 0.0 to 0.45 M in 30 minutes. Retention time was measured. The retention time of plAP samples containing no LPS was 20 minutes, whereas the retention time shifted to 18 minutes 10 after co-incubation with LPS. The shorter retention time of plAP samples containing LPS reflects an decreased negative charge of the complex, which indicates binding of LPS to AP enzymes thus neutralizing charges within the proteins. EXPERIMENT IV 15 To assess whether product inhibition occurred, which might explain the decline in serum AP activity, we tested the effect of unphosphorylated lipid A, which is the end-product of the enzyme reaction, upon AP activity. Formalin/macrodex-fixed cryostat sections (4 um) of the rat intestine, kidney and placenta were incubated with LPS, MgCl2 and lead-nitrate (Pb2NO3) in 0.2 M Tris/maleic acid buffer (pH 7.4) to 20 demonstrate phosphatase activity according to standard procedures (K. Poelstra et al. Lab. Invest 76:319, 1997, Am J. Pathol. 151: 1163, 1997). As documented before, rat intestinal and renal cryostat sections expressed abundant LPS dephosphorylating enzyme activity. LPS-dephosphorylating activity in the rat placenta was less abundant. The localization of this enzyme activity was similar to 25 the distribution of AP activity in all three organs. However, pre-incubation of these cryostat sections with lipid A (Monophosphoryl lipid A from Salmonella minnesota R595, List Biological Laboratories Inc., Campbell, USA; 1 mg/ml) strongly attenuated intestinal and renal phosphatase activity when LPS was subsequently added as substrate. No phosphatase activity was detectable in placenta's pre-incubated with lipid A. 30 From these data is has become clear that AP upon binding to LPS is temporarily not available for dephosphorylation of additional LPS. This may be explained by relatively high affinity of LPS to the binding site of AP and vice versa.
WO 00/37943 PCT/NL98/00722 11 LEGENDS TO THE FIGURES: Figure 1: Serum alkaline phosphatase levels in mice after administration of saline (i.v.), LPS (i.v.) 5 or E.coli bacteria (i.p.) at t=0 (n=4 per group). The diamond signifies saline, the square signifies E coli, the triangle signifies LPS. t is set in hr along x axis and AP activity is represented in U/L on y-axis Figure 2: 10 Changes in serum AP levels relative to the day of admission to the intensive care unit of the hospital, before and after the blood samples of patients became positive for bacteria or bacterial products (LPS). Patients were divided into two groups: patients with an established Gram-negative bacterial infection (n=16) and patients with an established Gram-positive bacterial infection (n=30). Patients with a mixed bacterial infection (n=18) 15 or with SIRS without identification of the bacterium are not presented here. The dark symbol signifies Gram negative. The light symbol signifies Gram positive. References: 20 Chemical derivatives of LPS of lipid A: 1. Qureshi N; Jarvis B; Takayama K; Sattar N; Hofmnan J; Stutz P: Natural and synthetic LPS and lipid a analogs or partial structures that antagonize or induce tolerance to LPS. Prog Clin Biol Res 1998; 397: 289-300 2. Brandenburg K; Kusumoto S; Seydel U: Conformational studies of synthetic lipid A 25 analogues and partial structures by infrared spectroscopy. Biochim Biophys Acta. 1997: 1329; 183-201 Conditions of enhanced serum AP levels: 3. Ross PD; Knowlton W: Rapid bone loss is associated with increased levels of 30 biochemical markers. J Bone Miner Res. 1998: 13; 297-302 4. Dourakis SP; Mayroyannis C; Alexopoulou A; Hadziyannis SJ: Prolonged cholestatic jaundice after endoscopic retrograde cholangiography. Hepatogastroenterology 1997: 44; 677-80 WO 00/37943 PCT/NL98/00722 12 Methods to determine serum AP: 5. Peake MJ; Pejakovic M; White GH: Quantitative method for determining serum alkaline phosphatase isoenzyme activity: estimation of intestinal component. J Clin pathol 1988: 41; 202-206 5 6. McComb RB; Bowers GN; Posen S: Measurement of alkaline phosphatase activity. In: Alkaline Phosphatase, Plenum Press, New York and London, 1979: Ch 7, pp 289-372.
Claims (29)
1. A method of diagnosis of onset of endotoxemia or sepsis due to Gram negative bacterial infection said method comprising monitoring of the degree of AP 5 occupancy of LPS binding sites on alkaline phosphatase in a sample of tissue or fluid derived from a patient, wherein the degree of AP occupancy is associated with presence or absence of Gram negative bacterial infection.
2. A method according to claim 1, wherein the degree of AP occupancy of LPS binding sites on alkaline phosphatase in the sample is lower than that of an 10 equivalent sample type of an individual free of Gram negative infection.
3. A method according to claim 1 or 2, wherein the degree of AP occupancy of LPS binding sites on alkaline phosphatase in a sample or tissue or fluid derived from a patient, is monitored over a period of time, wherein a decline of the degree of AP occupancy indicates Gram negative bacterial infection. 15
4. A method according to any of the preceding claims, wherein the degree of AP occupancy of LPS binding sites on alkaline phosphatase in the sample is determined and wherein onset of decline in the degree of AP occupancy indicates onset of Gram negative bacterial infection.
5. A method according to any of the preceding claims wherein the degree of 20 AP occupancy of LPS binding sites on alkaline phosphatase may also indicate a mixed or single infection of Gram negative and Gram positive bacteria.
6. A method according to any of the preceding claims wherein the sample is subjected to binding with a ligand for the LPS binding site on alkaline phosphatase followed by determination of the degree of binding of the ligand. 25
7. A method according to any of the preceding claims wherein the ligand for the LPS binding site on alkaline phosphatase is selected from the group consisting of naturally occurring ligands, chemically modified or genetically modified derivatives of natural LPS binding site binding substances, chemically produced ligands.
8. A method according to any of the preceding claims, wherein the sample is 30 subjected to binding with a ligand for the LPS binding site on alkaline phosphatase selected from LPS, Lipid A, an LPS binding site antibody against alkaline phosphatase, a Fab fragment with LPS binding site binding ability on alkaline phosphatase, a single chain fragment of an immunoglobulin having LPS binding site binding activity on WO 00/37943 PCT/NL98/00722 14 alkaline phosphatase.
9. A method according to any of the preceding claims, wherein the LPS binding site binding ligand has at least the affinity for the LPS binding site of alkaline phosphatase of LPS. 5
10. A method according to any of the preceding claims wherein the LPS binding site binding ligand has at least the affinity for the LPS binding site of alkaline phosphatase of lipid A.
11. A method according to any of claims 1-5 wherein the degree of AP occupancy of LPS binding sites on alkaline phosphatase is determined by assessment of 10 the dephosphorylating capacity of alkaline phosphatase in the sample.
12. A method according to claim 11, wherein the ratio of dephosphorylating alkaline phosphatase to non dephosphorylating alkaline phosphatase is determined.
13. A method according to claim 12, wherein the ratio is determined using the values obtained by assessment of total alkaline phosphatase activity using 15 biochemical methods to determine dephosphorylating activity and by assessment of total amounts of alkaline phosphatase using e.g. antibodies or otherwise discriminating entities and calculating the ratio of these values.
14. A method according to any of the preceding claims wherein the sample is from a cholestasis free patient. 20
15. A method according to any of claims 1-13 wherein the method also comprises a further assay of a sample from the patient for another disease related to increase of alkaline phophatase activity, said further assay employing a method avoiding determination of alkaline phosphatase level.
16. A method according to claim 15 wherein the further assay is carried out 25 when no decline in AP occupancy of LPS binding sites of alkaline phosphatase according to the method of any of claims 1-14 is detected.
17. A method according to any of the preceding claims, wherein the sample is taken from an individual at risk of Gram negative bacterial infection.
18. A method according to claim 17 wherein the sample is taken from an 30 individual either both prior to and following trauma or shortly after having undergone trauma, wherein the trauma in particular concerns surgery, burns or ischemic traumas.
19. A method according to any of the preceding claims wherein the sample is taken from an individual during hospitalisation. WO 00/37943 PCTINL98/00722 15
20. A method according to any of the preceding claims wherein the sample is taken a number of times over a period of time and the data are compared thus revealing the level of AP occupancy over time.
21. A method according to any of the preceding claims wherein the period 5 of time is as long as the individual is at risk of infection i.e. during hospitalisation or post trauma recovery.
22. A method according to any of the preceding claims wherein the result of the assay is compared to a standard value thus revealing whether the degree of AP occupancy is indicative of endotoxemia or sepsis or the risk thereof. 10
23. A method according to any of the preceding claims wherein the sample is a sample selected from the group consisting of blood and tissue, said blood sample for example being serum, said tissue being other than bone and said tissue for example being selected from liver and intestine.
24. A kit comprising alkaline phosphatase LPS binding site binding ligand 15 and instructions for carrying out an assay according to any of the preceding claims and optionally any additional components required for such assay e.g. detectable marker, buffer, containers and comparative samples or data charts e.g. standard curves or data concerning relevant data of alkaline phosphatase values.
25. A kit comprising alkaline phosphatase LPS binding site binding ligand 20 for carrying out an assay according to any of the claims 1-23 and any additional component required for such assay being selected from the following group consisting of detectable marker, buffer, containers, comparative samples, data charts e.g. standard curves or data concerning relevant data of alkaline phosphatase values. 25. A method for therapy of endotoxemia or sepsis said method comprising 25 administration of a pharmaceutically effective amount of the LPS binding site of alkaline phosphatase in a systemically acceptable form with the proviso the ligand is neither alkaline phosphatase nor a derivative of alkaline phosphatase having dephosphorylating activity.
26. A method for removing LPS from tissue or fluid said method comprising 30 contacting the LPS binding site of alkaline phosphatase with the tissue or fluid to be treated followed by separation of the LPS binding site and the tissue or fluid after the the LPS binding site has bound the LPS present in the fluid or tissue, with the proviso the ligand is neither alkaline phosphatase nor a derivative of alkaline phosphatase having WO 00/37943 PCT/NL98/00722 16 dephosphorylating activity.
27. A method of purification of AP itself from tissue or body fluids or other biological production systems with a compound with an LPS binding site of alkaline phosphatase such as LPS, lipid A or other ligand as described in the preceding claims. 5
28. Use of a compound with an LPS binding site of alkaline phosphatase such as LPS, lipid A or other ligand as described in the preceding claims as active compound in a medicament for therapy or diagnosis.
29. Use of a compound with an LPS binding site of alkaline phosphatase such as LPS, lipid A or other ligand as described in the preceding claims as active 10 compound in therapy or diagnosis.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/NL1998/000722 WO2000037943A1 (en) | 1998-12-21 | 1998-12-21 | Diagnosis of sepsis using the lps-binding moiety of alkaline phosphatase |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU1786999A true AU1786999A (en) | 2000-07-12 |
| AU764247B2 AU764247B2 (en) | 2003-08-14 |
Family
ID=19866467
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU17869/99A Ceased AU764247B2 (en) | 1998-12-21 | 1998-12-21 | Diagnosis of sepsis using the LPS-binding moiety of alkaline phosphatase |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1141717A1 (en) |
| JP (1) | JP2002533679A (en) |
| AU (1) | AU764247B2 (en) |
| HK (1) | HK1041048A1 (en) |
| WO (1) | WO2000037943A1 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030232401A1 (en) * | 2002-06-12 | 2003-12-18 | Pugia Michael J. | Bacterial test method by glycated label binding |
| AU2005210581B2 (en) * | 2004-02-04 | 2010-06-24 | Am-Pharma B.V. | Use of alkaline phosphatase for the detoxification of LPS present at mucosal barriers |
| KR101569334B1 (en) | 2013-12-20 | 2015-11-17 | 경북대학교 산학협력단 | Biomarker composition comprising raftlin for diagnosis of sepsis and the method of diagnosis using the same |
| KR102166110B1 (en) | 2014-01-24 | 2020-10-16 | 에이엠-파마 비.브이. | Chimeric alkaline phosphatase-like proteins |
| CN106459143A (en) | 2014-01-24 | 2017-02-22 | 安-法玛公司 | Downstream processing of an alkaline phosphatase |
| WO2020243697A1 (en) | 2019-05-31 | 2020-12-03 | Rhogen Biotech Llc | Compositions and methods for detoxifying bacterial endotoxins |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995005455A1 (en) * | 1993-08-13 | 1995-02-23 | Rijksuniversiteit Te Groningen | Pharmaceutical composition comprising phosphatase or a derivative thereof |
-
1998
- 1998-12-21 AU AU17869/99A patent/AU764247B2/en not_active Ceased
- 1998-12-21 JP JP2000589949A patent/JP2002533679A/en active Pending
- 1998-12-21 WO PCT/NL1998/000722 patent/WO2000037943A1/en not_active Application Discontinuation
- 1998-12-21 EP EP98962694A patent/EP1141717A1/en not_active Withdrawn
-
2002
- 2002-03-21 HK HK02102156.4A patent/HK1041048A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HK1041048A1 (en) | 2002-06-28 |
| AU764247B2 (en) | 2003-08-14 |
| JP2002533679A (en) | 2002-10-08 |
| WO2000037943A1 (en) | 2000-06-29 |
| EP1141717A1 (en) | 2001-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Clark et al. | Selective IgA deficiency in blood donors | |
| Ikemura et al. | False-positive result in Limulus test caused by Limulus amebocyte lysate-reactive material in immunoglobulin products | |
| Lucisano et al. | Lysosomal enzyme release from polymorphonuclear leukocytes induced by immune complexes of IgM and of IgG. | |
| Sörensen et al. | Platelet-activating factor and phospholipase A 2 in patients with septic shock and trauma | |
| KR101941308B1 (en) | Method for detectinon of intestinal, and blood-brain barrier permeability and testing materials thereto | |
| JPH03504412A (en) | Method for preparing high-molecular cell-associated protein of Campylobacter pylori and its use for serological detection of Campylobacter pylori infection | |
| JP2002503093A (en) | Pan-bacterial and pan-fungal identification reagents and methods of use | |
| US5484707A (en) | Assay for free secretory component and methods for monitoring organ rejection | |
| JP3579549B2 (en) | Use as a marker for diabetes or diabetic complications | |
| Roll et al. | No association of antibodies to glutamic acid decarboxylase and diabetic complications in patients with IDDM | |
| JP4903965B2 (en) | Inter-alpha-trypsin as a sepsis marker | |
| AU764247B2 (en) | Diagnosis of sepsis using the LPS-binding moiety of alkaline phosphatase | |
| US4673637A (en) | Method for detecting bacteria in urine and for treating rheumatoid arthritis, essential hypertension and other diseases associated with bacteriuria | |
| EP1843781B1 (en) | Composition for prevention, treatment and diagnosis of chronic inflammatory airway diseases | |
| Warrell | Bites by Russell's vipers (Daboia russelii siamensis) in Myanmar: effect of the snake's length and recent feeding on venom antigenaemia and severity of envenoming | |
| Crook et al. | Elevated serum lipoprotein (a) levels in young women with endometriosis | |
| Takagi et al. | Renal Histological Studies in Patients with Takayasu’s Arteritis: Report of 3 Cases | |
| Lind et al. | Observations on blood glucose and insulin determinations | |
| ES2903132T3 (en) | Delta-Like Ligand 1 for Diagnosis of Serious Infections | |
| JP2003315334A (en) | Quantitative method of bpi in body fluid | |
| Nielsen et al. | Meningococcal disease in congenital absence of the fifth component of complement | |
| RU2823997C1 (en) | Method for differential diagnosis of pyelonephritis and urolithiasis | |
| WO2010123069A1 (en) | Method for diagnosing autoimmune disease patient, in vitro diagnostic agent and therapeutic agent therefor | |
| Shentova et al. | Surrogate Markers of Intestinal Inflammation in Paediatric Patients with Inflammatory Bowel Disease | |
| JPH04503114A (en) | Staphylococcal fibronectin receptor antibody detection test |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC1 | Assignment before grant (sect. 113) |
Owner name: PHARMAAWARE IP B.V. Free format text: THE FORMER OWNER WAS: STICHTING VOOR DE TECHNISCHE WETENSCHAPPEN, RIJKSUNIVERSITEIT GRONINGEN |
|
| FGA | Letters patent sealed or granted (standard patent) |